The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer

International Journal of Cancer

Volumn 136, Issue 11, 2015, Pages 2717-2729

  Lee, Tae Gul ^a   Jeong, Eun Hui ^a   Kim, Seo Yun ^a   Kim, Hye Ryoun ^a   Kim, Cheol Hyeon ^a  

^a Korea Cancer Center Hospital   (South Korea)

Author keywords

BIBW2992; epidermal growth factor receptor; histone deacetylases inhibitor; T790M; WZ4002

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; N [3 [[5 CHLORO 2 [[2 METHOXY 4 (4 METHYL 1 PIPERAZINYL)PHENYL]AMINO] 4 PYRIMIDINYL]OXY]PHENYL]ACRYLAMIDE; VORINOSTAT; ACRYLAMIDE DERIVATIVE; ANTINEOPLASTIC AGENT; CASPASE; EGFR PROTEIN, HUMAN; ENZYME INHIBITOR; HYDROXAMIC ACID; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; CANCER CELL; CANCER CELL DESTRUCTION; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; IN VIVO STUDY; MOUSE; MUTATIONAL ANALYSIS; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CANCER TRANSPLANTATION; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG NEOPLASMS; METABOLISM; MUTATION; TUMOR CELL LINE;

ACRYLAMIDES; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AUTOPHAGY; CASPASES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXAMIC ACIDS; LUNG NEOPLASMS; MICE; MUTATION; NEOPLASM TRANSPLANTATION; PYRIMIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84924875404     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29320     Document Type: Article

References (49)

1. Pao W, Chmielecki J,. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010; 10: 760-74.
2. Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A,. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 2011; 364: 947-55.
3. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-92.
4. Pao W, Miller VA, Politi KA, Riely et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73.
5. Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008; 105: 2070-5.
6. Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005; 102: 7665-70.
7. Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinicallung cancer models. Oncogene 2008; 27: 4702-11.
8. Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012; 343: 342-50.
9. Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012; 13: 528-38.
10. Zhou W, Ercan D, Chen L, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009; 462: 1070-4.
11. Cress WD, Seto E,. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 2000; 184: 1-16.
12. Marks P, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001; 1: 194-202.
13. Yang XJ, Seto E,. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell 2008; 31: 449-61.
14. Glozak MA, Sengupta N, Zhang X, Seto E,. Acetylation and deacetylation of non-histone proteins. Gene 2005; 363: 15-23.
15. Kim SC, Sprung R, Chen Y, et al. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell 2006; 23: 607-18.
16. Yoo CB, Jones PA,. Epigenetic therapy of cancer: Past, present and future. Nat Rev Drug Discov 2006; 5: 37-50.
17. Nakagawa M, Oda Y, Eguchi T, et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 2007; 18: 769-74.
18. Marks PA, Dokmanovic M,. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Invest Drugs 2005; 14: 1497-511.
19. Bolden JE, Peart MJ, Johnstone RW,. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-84.
20. Lane AA, Chabner BA,. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27: 5459-68.
21. Jenuwein T, Allis CD,. Translating the histone code. Science 2001; 293: 1074-80.
22. Minucci S, Pelicci PG,. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 38-51.
23. Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010; 141: 69-80.
24. Nolan L, Johnson PW, Ganesan A, et al. Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? Br J Cancer 2008; 99: 689-94.
25. Wagner JM, Hackanson B, Lübbert M, Jung M,. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenet 2010; 1: 117-36.
26. Sharma NL, Groselj B, Hamdy FC, Kiltie AE,. The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers. BJU Int 2013; 111: 537-42.
27. Ono M, Hirata A, Kometani T, et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 2004; 3: 465-72.
28. Rho JK, Choi YJ, Lee JK, et al. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors. Mol Cancer Res 2009; 7: 1736-43.
29. Han W, Pan H, Chen Y, et al. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One 2011; 6: e18691.
30. Li YY, Lam SK, Mak JC, et al. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer. Lung Cancer 2013; 81: 354-61.
31. Shao Y, Gao Z, Marks PA, Jiang X,. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 2004; 101: 18030-5.
32. Rikiishi H,. Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. J Biomed Biotechnol 2011; 2011: 830260.
33. Shubassi G, Robert T, Vanoli F, et al. Acetylation: a novel link between double-strand break repair and autophagy. Cancer Res 2012; 72: 1332-5.
34. Trüe O, Matthias P,. Interplay between histone deacetylases and autophagy-from cancer therapy to neurodegeneration. Immunol Cell Biol 2012; 90: 78-84.
35. Kabeya Y, Mizushima N, Ueno T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000; 19: 5720-8.
36. Huang WP, Klionsky DJ,. Autophagy in yeast: a review of the molecular machinery. Cell Struct Funct 2002; 27: 409-20.
37. Mizushima N, Yoshimori T, Levine B,. Methods in mammalian autophagy research. Cell 2010; 140: 313-26.
38. Schweichel JU, Merker HJ,. The morphology of various types of cell death in prenatal tissues. Teratology 1973; 7: 253-66.
39. Gozuacik D, Kimchi A,. Autophagy as a cell death and tumor suppressor mechanism. Oncogene 2004; 23: 2891-906.
40. Oxnard GR, Arcila ME, Chmielecki J, et al. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 2011; 17: 5530-7.
41. Regales L, Gong Y, Shen R, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009; 119: 3000-10.
42. Janjigian YY, Groen HJ, Horn L, et al. Activity and tolerability of afatinib (BIBW2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J Clin Oncol 2011; 29 suppl: 486s (abstr 7525).
43. Nakagawa T, Takeuchi S, Yamada T, et al. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition. Cancer Res 2013; 73: 2428-34.
44. Chen MC, Chen CH, Wang JC, et al. The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells. Cell Death Dis 2013; 4: e810.
45. Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ,. Potential therapeutic applications of autophagy. Nat Rev Drug Discov 2007; 6: 304-12.
46. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G,. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007; 8: 741-52.
47. Eisenberg-Lerner A, Bialik S, et al. Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ 2009; 16: 966-75.
48. Djavaheri-Mergny M, Maiuri MC, Kroemer G,. Cross talk between apoptosis and autophagy by caspase-mediated cleavage of Beclin 1. Oncogene 2010; 29: 1717-9.
49. Fimia GM, Piacentini M,. Regulation of autophagy in mammals and its interplay with apoptosis. Cell Mol Life Sci 2010; 67: 1581-8.